These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

914 related articles for article (PubMed ID: 15780731)

  • 1. Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes.
    Lemesre JL; Holzmuller P; Cavaleyra M; Gonçalves RB; Hottin G; Papierok G
    Vaccine; 2005 Apr; 23(22):2825-40. PubMed ID: 15780731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
    Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
    Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphocytes of dogs immunised with purified excreted-secreted antigens of Leishmania infantum co-incubated with Leishmania infected macrophages produce IFN gamma resulting in nitric oxide-mediated amastigote apoptosis.
    Holzmuller P; Cavaleyra M; Moreaux J; Kovacic R; Vincendeau P; Papierok G; Lemesre JL
    Vet Immunol Immunopathol; 2005 Jul; 106(3-4):247-57. PubMed ID: 15963823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective humoral and cellular immunoprotective responses in Li ESAp-MDP vaccinated protected dogs.
    Bourdoiseau G; Hugnet C; Gonçalves RB; Vézilier F; Petit-Didier E; Papierok G; Lemesre JL
    Vet Immunol Immunopathol; 2009 Mar; 128(1-3):71-8. PubMed ID: 19046774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge.
    Rodríguez-Cortés A; Ojeda A; López-Fuertes L; Timón M; Altet L; Solano-Gallego L; Sánchez-Robert E; Francino O; Alberola J
    Vaccine; 2007 Nov; 25(46):7962-71. PubMed ID: 17942199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and characterization of new Leishmania promastigote surface antigens, LaPSA-38S and LiPSA-50S, as major immunodominant excreted/secreted components of L. amazonensis and L. infantum.
    Bras-Gonçalves R; Petitdidier E; Pagniez J; Veyrier R; Cibrelus P; Cavaleyra M; Maquaire S; Moreaux J; Lemesre JL
    Infect Genet Evol; 2014 Jun; 24():1-14. PubMed ID: 24614507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gentamicin-attenuated Leishmania infantum: cellular immunity production and protection of dogs against experimental canine leishmaniasis.
    Daneshvar H; Molaei MM; Kamiabi H; Burchmore R; Hagan P; Stephen Phillips R
    Parasite Immunol; 2010; 32(11-12):722-30. PubMed ID: 21039612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals.
    Gradoni L; Foglia Manzillo V; Pagano A; Piantedosi D; De Luna R; Gramiccia M; Scalone A; Di Muccio T; Oliva G
    Vaccine; 2005 Nov; 23(45):5245-51. PubMed ID: 16054272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response.
    Ramos I; Alonso A; Marcen JM; Peris A; Castillo JA; Colmenares M; Larraga V
    Vaccine; 2008 Jan; 26(3):333-44. PubMed ID: 18093705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant Forms of Leishmania amazonensis Excreted/Secreted Promastigote Surface Antigen (PSA) Induce Protective Immune Responses in Dogs.
    Petitdidier E; Pagniez J; Papierok G; Vincendeau P; Lemesre JL; Bras-Gonçalves R
    PLoS Negl Trop Dis; 2016 May; 10(5):e0004614. PubMed ID: 27223609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of a multicomponent DNA vaccine against visceral leishmaniasis in dogs.
    Saldarriaga OA; Travi BL; Park W; Perez LE; Melby PC
    Vaccine; 2006 Mar; 24(11):1928-40. PubMed ID: 16310897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serological evaluation of experimentally infected dogs by LicTXNPx-ELISA and amastigote-flow cytometry.
    Silvestre R; Santarém N; Cunha J; Cardoso L; Nieto J; Carrillo E; Moreno J; Cordeiro-da-Silva A
    Vet Parasitol; 2008 Nov; 158(1-2):23-30. PubMed ID: 18848397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Canine Leishmania vaccines: still a long way to go.
    Gradoni L
    Vet Parasitol; 2015 Feb; 208(1-2):94-100. PubMed ID: 25620293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gentamicin-attenuated Leishmania infantum: a clinicopathological study in dogs.
    Daneshvar H; Molaei MM; Afshar RM; Kamiabi H; Burchmore R; Hagan P; Phillips RS
    Vet Immunol Immunopathol; 2009 May; 129(1-2):28-35. PubMed ID: 19147233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination of dogs with six different candidate leishmaniasis vaccines composed of a chimerical recombinant protein containing ribosomal and histone protein epitopes in combination with different adjuvants.
    Poot J; Janssen LH; van Kasteren-Westerneng TJ; van der Heijden-Liefkens KH; Schijns VE; Heckeroth A
    Vaccine; 2009 Jul; 27(33):4439-46. PubMed ID: 19500553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum.
    Rafati S; Nakhaee A; Taheri T; Taslimi Y; Darabi H; Eravani D; Sanos S; Kaye P; Taghikhani M; Jamshidi S; Rad MA
    Vaccine; 2005 May; 23(28):3716-25. PubMed ID: 15882533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detailed analysis of an experimental challenge model for Leishmania infantum (JPC strain) in dogs.
    Poot J; Rogers ME; Bates PA; Vermeulen A
    Vet Parasitol; 2005 Jun; 130(1-2):41-53. PubMed ID: 15893068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-12 augments a Th1-type immune response manifested as lymphocyte proliferation and interferon gamma production in Leishmania infantum-infected dogs.
    Strauss-Ayali D; Baneth G; Shor S; Okano F; Jaffe CL
    Int J Parasitol; 2005 Jan; 35(1):63-73. PubMed ID: 15619517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis.
    Fujiwara RT; Vale AM; França da Silva JC; da Costa RT; Quetz Jda S; Martins Filho OA; Reis AB; Corrêa Oliveira R; Machado-Coelho GL; Bueno LL; Bethony JM; Frank G; Nascimento E; Genaro O; Mayrink W; Reed S; Campos-Neto A
    Vet Res; 2005; 36(5-6):827-38. PubMed ID: 16120256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody response in dogs experimentally infected with Leishmania infantum: infection course antigen markers.
    Carrera L; Fermín ML; Tesouro M; García P; Rollán E; González JL; Méndez S; Cuquerella M; Alunda JM
    Exp Parasitol; 1996 Mar; 82(2):139-46. PubMed ID: 8617340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.